Physician profile
Michael Yablonsky
NPI 1811960503
$1,849.82
in general payments reported to CMS, 2019-2025
28 companies · $14.95 in 2025
The $14.95 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $60.02 · 2021: $38.16 · 2022: $387 · 2023: $188 · 2024: $83.65 · 2025: $14.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $221.20 | 2019 | |
| Abbvie INC. | $191.05 | 2019-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $155.21 | 2019-2022 | |
| Dermira, INC. | $125.01 | 2019 | |
| Pfizer INC. | $118.12 | 2019-2023 | |
| Genzyme Corporation | $117.28 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $114.05 | 2019 | |
| Ucb, INC. | $76.92 | 2019-2024 | Bimzelx |
| Janssen Biotech, INC. | $74.22 | 2020-2022 | |
| Galderma Laboratories, L.P. | $72.54 | 2019-2023 | Twyneo, Aklief, Epsolay |
| Lilly USA, LLC | $71.69 | 2019-2023 | Olumiant, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.44 | 2022-2023 | Spevigo |
| Amgen INC. | $51.78 | 2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $51.56 | 2022-2023 | Sotyktu |
| Genentech USA, INC. | $40.39 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $35.79 | 2022 | |
| Leo Pharma INC. | $35.24 | 2019-2022 | |
| Allergan, INC. | $28.48 | 2019 | |
| Dusa Pharmaceuticals, INC. | $23.64 | 2019 | |
| Biofrontera INC. | $23.35 | 2019 | |
| Mayne Pharma Commercial LLC | $21.22 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.98 | 2023 | Odomzo, Blu-U |
| Solta Medical, A Division of Bausch Health US, LLC | $20.92 | 2019 | |
| Fidia Pharma USA INC. | $20.77 | 2023 | Triluron, Hymovis |
| Vyne Pharmaceuticals INC. | $20.34 | 2021 | |
| Prugen, INC. Pharmaceuticals | $19.58 | 2019 | |
| Kyowa Kirin, INC. | $19.54 | 2022 | |
| Incyte Corporation | $19.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yablonsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.